Taizhou Junshi Biomedical Technology Co., Ltd.

To compare the overall survival (OS) and progression-free survival (PFS) assessed by an independent imaging review committee according to RECIST v1.1 criteria between toripalimab plus bevacizumab and sorafenib as first-line treatment for advanced hepatocellular carcinoma.

To evaluate the efficacy and safety of toripalimab in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma after at least two lines of treatment have failed, including objective response rate (ORR), overall survival (OS), duration of response (DOR), disease control rate (DCR), progression-free survival (PFS) assessed by independent imaging review and investigators according to RECIST v1.1 criteria, and iORR, iDoR, iDCR, iPFS assessed by independent imaging review and investigators according to iRECIST criteria.

To compare the progression-free survival (PFS) of toripalimab combined with axitinib and sunitinib alone in the first-line treatment of advanced renal cell carcinoma, as assessed by an independent radiological review committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.